Age-Dependent Brain Gene Expression and Copy Number Anomalies in Autism Suggest Distinct Pathological Processes at Young Versus Mature Ages

doi:10.1371/journal.pgen.1002592

PLoS Genet. 2012 March; 8(3): e1002592.

Published online 2012 March 22. doi: 10.1371/journal.pgen.1002592

PMCID: PMC3310790

Copyright Chow et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Age-Dependent Brain Gene Expression and Copy Number Anomalies in Autism Suggest Distinct Pathological Processes at Young Versus Mature Ages

Maggie L. Chow,^#¹ Tiziano Pramparo,^#^1,² Mary E. Winn,^3,⁴ Cynthia Carter Barnes,¹ Hai-Ri Li,⁵ Lauren Weiss,⁶ Jian-Bing Fan,⁷ Sarah Murray,³ Craig April,⁷ Haim Belinson,² Xiang-Dong Fu,⁵^¶ Anthony Wynshaw-Boris,²^¶ Nicholas J. Schork,³^¶^* and Eric Courchesne¹^¶^*

¹Department of Neuroscience, NIH–UCSD Autism Center of Excellence, School of Medicine, University of California San Diego, La Jolla, California, United States of America

²Division of Medical Genetics, Department of Pediatrics and Institute of Human Genetics, School of Medicine, University of California San Francisco, San Francisco, California, United States of America

³Scripps Genomic Medicine and The Scripps Translational Sciences Institute (STSI), La Jolla, California, United States of America

⁴Graduate Program in Biomedical Sciences, Department of Medicine, University of California San Diego, La Jolla, California, United States of America

⁵Department of Cellular and Molecular Medicine, School of Medicine, University of California San Diego, La Jolla, California, United States of America

⁶Department of Psychiatry, School of Medicine, University of California San Francisco, San Francisco, California, United States of America

⁷Illumina, San Diego, California, United States of America

Greg Gibson, Editor

Georgia Institute of Technology, United States of America

^#Contributed equally.

* E-mail: nschork/at/scripps.edu (NJS); Email: ecourchesne/at/ucsd.edu (EC)

Conceived and designed the experiments: J-BF X-DF AW-B NJS EC. Performed the experiments: MLC TP H-RL CA. Analyzed the data: MLC TP MEW LW. Contributed reagents/materials/analysis tools: NJS AW-B EC X-DF LW. Wrote the paper: MLC TP AW-B NJS EC. Performed detailed review of the clinical data from the post-mortem individuals that are depicted in Table S1: CCB. Oversaw the processing of the genotyping assays: SM. Performed the second set of Bioanalyzer experiments to assess RNA quality: HB.

¶ These authors were joint senior authors on this work.

Received September 27, 2011; Accepted January 22, 2012.

This article has been cited by other articles in PMC.

Abstract

Autism is a highly heritable neurodevelopmental disorder, yet the genetic underpinnings of the disorder are largely unknown. Aberrant brain overgrowth is a well-replicated observation in the autism literature; but association, linkage, and expression studies have not identified genetic factors that explain this trajectory. Few studies have had sufficient statistical power to investigate whole-genome gene expression and genotypic variation in the autistic brain, especially in regions that display the greatest growth abnormality. Previous functional genomic studies have identified possible alterations in transcript levels of genes related to neurodevelopment and immune function. Thus, there is a need for genetic studies involving key brain regions to replicate these findings and solidify the role of particular functional pathways in autism pathogenesis. We therefore sought to identify abnormal brain gene expression patterns via whole-genome analysis of mRNA levels and copy number variations (CNVs) in autistic and control postmortem brain samples. We focused on prefrontal cortex tissue where excess neuron numbers and cortical overgrowth are pronounced in the majority of autism cases. We found evidence for dysregulation in pathways governing cell number, cortical patterning, and differentiation in young autistic prefrontal cortex. In contrast, adult autistic prefrontal cortex showed dysregulation of signaling and repair pathways. Genes regulating cell cycle also exhibited autism-specific CNVs in DNA derived from prefrontal cortex, and these genes were significantly associated with autism in genome-wide association study datasets. Our results suggest that CNVs and age-dependent gene expression changes in autism may reflect distinct pathological processes in the developing versus the mature autistic prefrontal cortex. Our results raise the hypothesis that genetic dysregulation in the developing brain leads to abnormal regional patterning, excess prefrontal neurons, cortical overgrowth, and neural dysfunction in autism.

Author Summary

Autism is a disorder characterized by aberrant social, communication, and restricted and repetitive behaviors. It develops clinically in the first years of life. Toddlers and children with autism often exhibit early brain enlargement and excess neuron numbers in the prefrontal cortex. Adults with autism generally do not display enlargement but instead may have a smaller brain size. Thus, we investigated DNA and mRNA patterns in prefrontal cortex from young versus adult postmortem individuals with autism to identify age-related gene expression differences as well as possible genetic correlates of abnormal brain enlargement, excess neuron numbers, and abnormal functioning in this disorder. We found abnormalities in genetic pathways governing cell number, neurodevelopment, and cortical lateralization in autism. We also found that the key pathways associated with autism are different between younger and older autistic individuals. These findings suggest that dysregulated gene pathways in the early stages of neurodevelopment could lead to later behavioral and cognitive deficits associated with autism.

Introduction

Clinical and subclinical manifestations of autism begin during the first years of life [1]. Neuroimaging studies of living infants and young children with autism have revealed abnormal brain overgrowth in the majority of cases, particularly in prefrontal, temporal and amygdala regions [2]–[13]. These studies have also shown abnormal functional asymmetry and activation in the cortex and cerebellum [14]–[16]. Children with autism have 67% excess neuron numbers in the prefrontal cortex, a substantial pathology that points to disruption of early developmental mechanisms that govern neuron numbers, and an 18% increase in brain weight at autopsy [17]. However, by late adolescence and early adulthood, the autistic brain commonly displays neuron loss and cortical thinning and is no longer enlarged [2], [8], [13], [18]. Therefore, the underlying developmental molecular defects in the majority of autistic cases seem likely to be most evident at younger rather than older ages.

The average age of individuals studied in more than fifty postmortem analyses of the autistic brain is 22 years [19], making it difficult if not impossible to comprehensively assess early developmental molecular pathologies associated with autism. In studies combining both young and adult autistic brain tissue, transcript and protein expression patterns suggest that cortical patterning, synaptic [20], apoptotic [21], immune [20], [22], and inflammatory [23] aberrances in addition to dysregulation of neurotransmitter systems [24] may be involved in autism. None of these molecular pathologies at older ages, however, can explain the 67% excess prefrontal neuron numbers and brain enlargement at younger ages in autism.

Thus, there seems to be a gap between neuroanatomical and cellular abnormalities reported for autism at younger ages and molecular pathologies in autism at older ages. Molecular pathologies specifically present at younger ages in autism are largely unknown and unexplored. Also, whether some molecular abnormalities detected in the older autistic brain reflect conditions unique to the older brain and whether others are common to both younger and older autistic brains are unknown. Genome-wide analyses of the genes, pathways and processes that exhibit dysregulation specifically in the young autistic brain have not been pursued to a great degree. This is particularly true for the prefrontal and temporal cortex, where abnormalities of growth and function during early development are pronounced and likely to contribute significantly to social, communication, language and emotional deficits associated with autism. Additionally, although copy number variation (CNV) has been hypothesized to play an important role in the pathogenesis of autism [25], [26] and may underlie important differences in gene expression, CNVs identified in brain tissue from individuals with autism have not been examined in relation to aberrant brain gene expression from the same tissue samples.

We examined the linked hypotheses that underlying neuroanatomical differences between younger and adult individuals with autism are a result of differences in molecular pathology. We hypothesize that some molecular pathologies at younger ages in autism may provide insight into the very early neural developmental processes that lead to the disorder. To do so, we identified abnormal genetic pathways in the young autistic brain, determined expression patterns that distinguished the young from the adult autistic brain and identified evidence for gene expression dysregulation that is age-independent using genome-wide expression and genotyping techniques. We found age-dependent gene expression differences between young and adult autistic brains as well as rare and common genetic variants associated with autism that have important roles in neurodevelopment.

Results

First, we analyzed genome-wide expression of 57 frozen samples of dorsolateral prefrontal cortex (DLPFC, BA 9/46; Table S1) using a DASL-based platform on the Illumina Human-Ref8 v3 microarray [27], [28]. Thirty-three samples in total passed quality control measures (Text S1): 16 of these samples were from young postmortem males (2–14 y; autism

9, control

7) and 17 were from adult males (15–56 y, autism

6, control

11). Though RNA Integrity Numbers (RIN) are not predictive of array quality [29], multiple RIN assessments were used to determine RNA quality (Table S1). We found no significant differences between the RINs of the autism and control groups (t

0.16, DF

20, p

0.87).

Two-way analysis of variance (ANOVA) and post-hoc pair-wise ANOVA-based comparisons were performed to identify genes exhibiting expression differences in young autistic vs. young control DLPFC compared to adult autistic vs. adult control DLPFC. An overall ANOVA-based F-test p-value<0.05 [empirical false discovery rate (FDR), not threshold, FDR

0.27] was used to identify genes showing an effect of interaction between age and diagnosis for further analyses. From the two-way ANOVA results, we attempted to tease out expression differences between: 1) young autism, 2) young control, 3) adult autism and 4) adult control groups.

Of the genes exhibiting an effect of interaction from ANOVA-based F-tests with p-values<0.05, 102 genes resulted in ANOVA-based post-hoc contrasts between young autistic and control groups with p-value<0.05 (Figure S1). Seven hundred thirty six genes resulted in an ANOVA-based post-hoc contrast between adult autistic and control cases (p-value<0.05). Finally, an overall ANOVA-based F-test p-value<0.05 (empirical FDR

0.13) was performed to assess the main effect of diagnosis across all autistic and control cases independent of age. Two thousand seventeen genes resulted in this contrast with p-value<0.05. Genes common between the three comparisons are shown in Figure S1.

Genes exhibiting a diagnosis main effect and a post-hoc pairwise contrast (e.g., autism vs. control, adult vs. young; p-value<0.05) were further subjected to enrichment analyses in the MetaCore software suite (MetaCore from GeneGo Inc.) as well as the online enrichment program DAVID [30], [31]. By focusing on genes exhibiting a diagnosis main effect, we explored pathological mRNA expression in autism irrespective of age. qPCR validation verified expression differences on a subset of the differentially expressed genes (Figure S2).

Genes regulating cell number, genetic integrity, and neural patterning are dysregulated in young autistic cases

Since early brain overgrowth and the clinical onset of autistic symptoms occur at young ages in autism, we focused on unique gene expression differences between autistic and control cases below the age of 14 years to identify genes that may be dysregulated early in autism pathogenesis. One hundred two genes were differentially expressed in young autistic cases compared with the young control group and exhibited a diagnosis x age group interaction effect (p-value<0.05, empirical FDR

0.27; Table S2). Many of these genes were previously identified autism candidate loci based on the literature (Table S3).

Pathway enrichment analyses of these 102 genes via the MetaCore software suite (defining an enriched pathway as having an enrichment p-value<0.05 and empirical FDR<0.1) suggested that DNA damage-response, cell cycle and apoptosis-related MetaCore pathways (‘M-Pathways’) were significantly altered (Table 1, Young autism versus young control map folders). Key players such as BRCA1 and CHK2 were downregulated. Most significantly dysregulated M-Pathways in this category included the DNA-damage-induced response and role of NFBD1 in DNA damage response. A Development-Neurogenesis Process Network, Development-Neurogenesis (p

1.09E-03, 6/192 network objects), was also significantly altered.

Table 1

MetaCore Pathway Map Folders (left) and M-Pathways (right) in three ANOVA-based analyses.

We additionally annotated all 102 genes using DAVID and identified overlapping sets of 12, 19, 7 and 16 genes involved in DNA damage/cell cycle, apoptosis, immune signaling and neurogenesis and neural development (Figure 1), respectively. Of the 7 immune response genes, 4 (FAS, BCL3, GREM1 and FOSL2) were also found to contribute to apoptosis. Neurogenesis and neural development pathways included the WNT pathway and were driven by dysregulation of the WNT3 gene. WNT pathway genes are known to regulate cell proliferation, cell fate and patterning during embryogenesis [32]. Downstream components of the WNT pathway, such as Dvl1, are also known to regulate social behavior in mouse models [33]. In addition, we found significant downregulation of genes involved in neural patterning and differentiation, such as FGF1, HOXD1, NDE1, NODAL, PCSK6 and GREM1 (Figure 1, Table S2).

Figure 1

Dysregulated gene expression in developmental M-Pathways and Process Networks in young autistic prefrontal cortex.

Expression anomalies of genes involved in DNA damage, cell cycle and apoptosis may contribute to abnormal brain growth by increasing production or reducing elimination of neurons during development. Dysregulated neural patterning and differentiation genes may lead to abnormal cellular organization and cytoarchitecture. For example, HOX and DLX family genes play important roles in vertebrate patterning and are important for neuronal subtype differentiation [34]. Moreover, NODAL controls dorsal mesoderm induction, anterior patterning and initiation of left-right asymmetry during gastrulation [35]. These findings suggest that in the young autistic brain, genetic regulation of cell number, genetic integrity and neural patterning is disturbed.

Genes regulating signaling, repair, and response pathways are dysregulated in adult autistic cases

As a complement to the analyses of the young autistic brain, we compared the genes dysregulated in young autistic cases to those dysregulated in adult autistic cases. We identified genes using the same ANOVA diagnosis x age interaction effect p-value criterion but with emphasis on genes differentially expressed in adult autistic brains relative to adult control brains (defined as cases ≥15 years of age). Seven hundred thirty six genes were differentially expressed based on this analysis (Figure S1, Table S4). These genes were also analyzed with MetaCore for functional enrichment. The 3 most significant MetaCore Map Folders (‘Map Folders’: a label MetaCore provides to sets of genes with an overarching function of pathway participation) included cell differentiation, mitogenic signaling and apoptosis genes (Table 1, Adult autism versus adult control map folders, Figure 2A; p<0.05, FDR<0.1). Dysregulated pathways specific for the adult brain included multiple signaling and remodeling functions in neurons and glia (Table 1, Adult autism versus adult control map folders). M-Pathway categories that were dysregulated in adults but not young cases included development, signaling and oxidative stress pathways (Table 1, Figure 2B).

Figure 2

Dysregulated gene expression in top three Map Folders in adult autistic prefrontal cortex and differentially affected M-Pathways of young and adult autistic cases.

The Cell Differentiation Map Folder included significantly dysregulated genes RELN, BTRC, BMP4, MAPK10 and NTRK3 (Figure 2A). This Map Folder also included suggested dysregulation of the ‘Activin A in Cell Differentiation and Proliferation’ pathway, which involved the genes LHB, NODAL, STAR, CDKN1A, PRKAR1A and ADCY6. Genes playing multiple functions in all three top map folders included MAPK12, CDKN1A, NTRK3, PRKAR1A, PIK3CA, CASP9, MAPK10, ADCY6 and MAGED1 (Figure 2A). Notably, Tissue Remodeling and Wound Repair-related genes also exhibited dysregulation in adult autistic cases (Table 1, Adult autism versus adult control map folders).

These analyses suggest that in the adult autistic brain, cell differentiation, mitogenic, apoptotic and remodeling and repair functions could be components of recovery responses, in accordance with previous reports [22], [23], [36]. They could, however, also be signatures of ongoing reparatory neurogenesis processes [37]. For example, the Activin A signaling pathway is expressed by neurons following injury and is essential for adult neurogenesis [38], [39]. BTRC inhibits the beta-catenin (CTNNB1) pathway [40], which in adult animals is upregulated after insults such as seizures [41] and promotes adult neurogenesis [42]. Furthermore, BMP4 expressed in adult subventricular zones serves to inhibit neurogenesis [43]. Thus, it appears that aberrant signaling and repair processes may distinguish adult autistic cases from young cases.

Genes important in development were dysregulated across both young and adult autistic cases

Finally, we examined genes showing a main effect of diagnosis to identify differentially expressed between autistic and control cases independent of age (i.e., we did not confine attention to genes exhibiting diagnosis x age interaction effects or age-specific effects). More than 2000 such genes were detected based on a simple contrast between autism and control brains (p<0.05, empirical FDR

0.13; Figure S1, Table S5). Enrichment analyses of these genes using MetaCore suggested that seventeen Map Folders were altered in all autistic brains (p<0.05, FDR

0.1; Table 1, Diagnosis main effect map folders). The three most significant Map Folders included DNA-damage response, apoptosis and immune system response functions (Figure 3, Figure S3). In addition, the top 25 M-Pathways (Table 1, Diagnosis main effect map folders, Table S6) included cell cycle [14-3-3 (YWHAZ), CDC25A, CDCD25C, ATRX], proliferation [CTNNB1 (beta-catenin), FSHB, PRKACB, PRKCZ], apoptosis (BAD, CASP8, CASP10, MDM2), cytoskeleton and extracellular matrix remodeling (ErbB4, MMP2, NID1, TIMP1, COL4A3) and growth and development [RELN, ROBO1, ADORA2A, p21 (CDKN1A), 14-3-3, HGF, FGFRL1, TSC1] functions. Specifically, the p53 signaling pathway and the PTEN pathway were among these dysregulated M-Pathways (Table 1, Diagnosis main effect map folders).

Figure 3

Dysregulated gene expression in top two MetaCore Map Folders in autism independent of age.

A number of genes in these M-Pathways have known functions in neuronal development: PTEN signaling regulates proliferation [44] and is associated with macrocephaly in autism [45], [46]. TSC1 is mutated in tuberous sclerosis, acts downstream of PTEN in the mTOR pathway [47] and affects cortical lamination, neuronal migration and axon pathfinding [48]. CTNNB1, a key member of the WNT pathway, regulates cerebral cortical size. CTNNB1 transgenic mice have enlarged and folded cortices [49]. Furthermore, RELN is critical for human neuronal migration [50] and has been previously linked to autism [51]. Genes differentiating autistic cases from controls independent of age have important developmental, immune and cytoskeletal remodeling functions.

Finally, given the novel cytoskeletal age-independent M-Pathways identified in this analysis, we revisited the 102 significant genes identified in the young autism vs. control analysis. We found 17 cytoskeletal and matrix remodeling genes (Figure 1). These analyses support a role for cytoskeletal dysregulation in young autistic brains as well. Cytoskeletal elements have been linked to defects in neuronal migration in other neurodevelopmental disorders such as lissencephaly [52].

Comparison with a published functional genomic study shows overlap in repair and immune response genes

Due to commonalities between previously identified candidate loci and the genes we found to exhibit expression differences between young autism vs. control, we also investigated similarities between the genes we identified and those identified in a recent functional genomic study. We compared genes showing a main effect of diagnosis in the present study with differentially expressed genes implicated recently by Voineagu et al. [20].

Twenty-five probes detected as p<0.05 in comparing autism and control cases and 21,564 probes detected as p>0.05 in both studies were identified as overlapping (p<0.0001). Among the probes detected at p<0.05 were 6 genes important for Tissue Remodeling and Wound Repair (p

1.622E-4, FDR<0.05) and 7 genes important for Immune System Response (p

4.772E-4, FDR<0.05). Ultimately, we found some consistency between genes detected in our analyses with those of a previous functional genomic study, particularly within domains of repair and immune response.

Genetic variation may underlie cell cycle and cytoskeleton gene dysregulation

To further investigate the findings of dysregulated genetic functions in young autistic cases particularly, we determined whether CNVs in autistic cases were distinct from those in controls. We genotyped prefrontal cortex samples from 55 of the 57 total autistic and control cases in our study. After quality control, CNV enrichment was analyzed in 30 DLPFC cases from male and female autistic and control cases (Table S1) using PennCNV with GC adjustment and CNVision programs [53], [54]. Nearly all (>99%) brain-derived CNVs in autistic and control cases were deletions (Table S7, Table S8). There were no differences between autistic and control cases in numbers of CNVs, numbers of genes per CNV or average CNV size (Figure S4).

Restricting analysis to male cases, genes identified in the autistic group were enriched in cell cycle (mitosis and S phase, including BUBR1, Cyclin B, BRCA1, RAD51, CRM1, RFC2 and LIS1) and cytoskeleton (spindle and cytoplasmic microtubules, including CLIP170, Tubulin alpha, Dynein light and heavy chains, DNAL1 and ROD) GeneGO Process Networks. No significant enrichment was identified in the gene content of controls (Figure 4). Similar network enrichment was noted in male autistic cases after filtering out common, non-pathogenic CNVs (Materials and Methods), while no significant network enrichment was found in controls (Figure 4). Notably, BRCA1 expression was found to be dysregulated in the young autistic brain (Figure 1) and predicted as deleted in the CNV analysis (Table S7). Subsequent enrichment analysis of CNVs present in male and female autistic and control cases yielded similar results (Figure S4). These results are consistent with the above described gene expression results showing abnormal expression of cell cycle and developmental pathways in the autistic cases.

Figure 4

MetaCore process networks and network maps in autism based on gene deletions located in CNVs from DLPFC, and genetic association results.

To extend these genotypic findings and specifically test whether common variants of cell cycle genes are associated with autism, we determined whether common variants in processes involved in cell cycle and other hypothesized regulatory processes were associated with autism using two previously analyzed SNP datasets: one from the Autism Genetic Resource Exchange (AGRE) and National Institutes of Mental Health genotyped at the Broad Institute and Johns Hopkins Medical Institute (Broad/JHMI) and another from AGRE genotyped at the Children's Hospital of Philadelphia (CHOP) [55], [56]. Set-based association analysis was applied to the Broad/JHMI dataset (Materials and Methods). Four sets of genes postulated to be involved in brain overgrowth (cell cycle, WNT pathway, growth factors and apoptosis) were used as experimental sets for analysis, while other postulated pathological processes such as synaptogenesis and inflammation were used as controls.

We found nominal associations of only cell cycle-related genes with ASD (Figure 4, p

0.037). Cell cycle genes were then subdivided into twenty-one subgroups. Genes regulating cell cycle senescence (p

0.011), the G2-M phase transition (p

0.028) and the G0-G1 phase transition (p

0.051) in particular were associated with autism in the Broad/JHMI dataset (Figure 4). Because these analyses were not statistically corrected for the number of pathways considered, the findings were replicated for the three significant subcategories (p<0.05) of cell cycle genes using the independent CHOP dataset (Figure 4). Two of the subcategories (senescence and G0-G1 phase transition) were replicated (p<0.0328 and p<0.0093 respectively), while the third (G2-M phase transition) was not. These results suggest that abnormal expression of cell cycle and developmental pathways may originate from genetic variation.

Discussion

Using genome-wide expression and CNV detection techniques, we discovered specific developmental pathways and processes in the prefrontal cortex that are significantly abnormal in younger autistic cases, other non-developmental processes that are dysregulated in older autism cases and, finally, processes common across younger and older ages in autism. Age-dependent gene expression alterations may underlie the differences in cellular and neuroanatomical pathologies between young and adult ages in autism that have been previously reported in MRI and postmortem research [13], [19]. In addition, we uncovered possible genotypic sources of developmental abnormalities in autism.

The young autistic prefrontal cortex displays dysregulated developmental genes

It is widely held that maldevelopment of the prefrontal cortex, in conjunction with several other cortical and subcortical regions, plays a pivotal role in the social, communication, cognitive and emotion processing deficits in autism. In the present study, the young autistic prefrontal cortex displayed disturbances in critical developmental pathways and processes that govern cell number, cortical patterning and differentiation, including those regulating proliferation, cell cycle, DNA damage response and apoptosis and survival. We hypothesize that such dysregulation could be the basis of the 67% excess neuron numbers also reported for prefrontal cortex in children with autism [17]. The top dysregulated pathway map in the young autistic brain was the A2A receptor signaling pathway (Table 1, Diagnosis main effect map folders). Adenosine receptors play important roles for both brain development and function including the regulation of neuronal stem cell proliferation (via nitric oxide signaling) [57], synaptic plasticity, motor function, cognition and emotion-related behaviors. This pathway has been a therapeutic target for studies of other complex neurologic and psychiatric disorders [58].

We also found strong evidence of abnormalities in cortical patterning pathways that regulate normal anterior/posterior and dorsal/ventral patterning as well as right/left asymmetry. At young ages in autism, MRI evidence indicates disruption of normal cortical patterning with gray matter enlargement greatest in anterior dorsolateral prefrontal cortex and least in posterior occipital and ventral orbital prefrontal cortex [3], [6], [19]. It will be important to further investigate the possible role that genetic dysregulation of neural patterning may play in causing abnormal left/right functional and structural asymmetries in addition to abnormal anterior/posterior and dorsal/ventral gradients that have been reported in autistic infants, children and adults [3], [6], [14], [15], [19], [XPATH ERROR: unknown variable "next".]. Dysregulation of proliferation, cell cycle and apoptosis may be involved in early brain overgrowth in autism and excess neuron numbers in the prefrontal cortex [17] and could therefore contribute to dysfunction at the neural systems level [19], [26], [60], [61]

The adult autism prefrontal cortex displays arrested growth and degeneration

In contrast to the younger autistic brain [62], the adult autistic brain shows evidence of neuron loss, reduced or arrested growth, cortical thinning and possible degeneration. It has been speculated that such pathologies may be related directly or indirectly to the earlier pathological overgrowth. It is known that the functions of genes are modulated by the age of the organism, such that dysregulation of the same gene in both young and adult autistic cases may have differing consequences. Genes such as BMP4 and BTRC, which have important functions in neurodevelopment, may regulate recovery functions such as neurogenesis in the adult brain [63]–[65]. Furthermore, we found that genes involved in cell differentiation, including RELN, BMP4, NODAL and NTRK3, and tissue remodeling and wound repair are dysregulated in adults. Though the literature on adult neurogenesis and cell differentiation is sparse, recent studies propose that the brain activates these mechanisms in response to injury in the neocortex [66], [67]. In the context of brain overgrowth, these data suggest the hypothesis that reactive reorganization of functional genetic networks and processes may occur in the adult autistic brain. Such functional reorganization of genetic modules or networks has recently been described for systems that regulate DNA-damage responses [68].

Age-independent differential expression represents pathological developmental processes

To complement analyses of age-specific expression pathology in autism, we also identified gene expression abnormalities in autism that were age independent. Among the most abnormally expressed genes were those that regulate DNA-damage response, apoptosis and immune system response functions. These genetic systems play important roles during development of the central nervous system [69]–[71] and suggest that the brain in autism arises from defects during this critical period. Several lines of evidence indicate that immune system responses closely participate in the neuropathogenesis of ASD both at young and adult ages. Although little is known about this role, both inflammatory and autoimmune mechanisms are necessary for normal neurodevelopment and are found to be altered in ASD [72]. Microglia activation and increases in inflammatory cytokine and chemokine production have direct effects on neuronal development by affecting cellular proliferation, migration and differentiation as well as synapse formation [72]. For example, TNF-α can modulate neuronal cell proliferation or cell death and plays an important role in synaptic pruning [73], [74]. In addition, auto-antibodies may affect receptor function, activate neuronal and glial cells and induce cellular damage or death [72].

More work remains to be done, however, to uncover the significance of these pathways in the postnatal brain. These results may point to mechanisms in the brain that are continuously pathological throughout the lifespan in autism and suggest possible candidates for genetic therapies.

Genes in common with a previous genetic study support pathway results

While large sample in vivo studies, such as Pinto et al. [26], have identified potential functional genomic abnormalities in autism, biological validation requires postmortem studies, such as the present one and Voineagu et al. [20]. The comparison of findings between the present study and Voineagu et al. [20] demonstrates a consistent overlap involving several pathways including repair- and immune-related processes.

We speculate that the aberrances in these genes, which may be distinct from individual to individual, may collectively underlie the repair or response mechanisms in the mature autistic brain. Commonalities across autistic brains may converge at the level of disturbances in these genetic pathways, and monitoring most commonly affected pathways across functional genomic studies may help subgroup different pathogenic mechanisms.

Though these genetic pathways with high impact on autism susceptibility may be similar between studies, there are also copious pathways that are disparate. The differences in the results between our study and Voineagu et al. [20] may be due to genetic heterogeneity, different criteria for sample selection and age and gender distribution. For example, although our studies assayed a similar number of postmortem cases, our sample consisted of all male autistic and control cases, while that of Voineagu et al. [20] consisted of 36% female autistic and 6% female control cases. Also, to identify gene expression abnormalities in the young autistic brain, we compared expression in the young autistic brain to the young control brain, while Voineagu et al. [20] lacked young controls. Thus, some effects that we observed may not have been identified in Voineagu et al. [20] because of differences in study design.

Copy number anomalies in autism

Our analyses using mRNA and DNA from the same cortices suggest that a large and heterogeneous array of genes and gene expression abnormalities regulate multiple foundational prenatal processes critical to cortex formation. Although DNA defects vary from autistic case to case, the diverse genetic deletions seem to underlie a relatively common biological theme, hitting a shared set of gene pathways that impact cell cycle, DNA damage detection and repair, migration, neural patterning and cell differentiation. The set of functional gene pathways identified by our direct analyses of autistic brain tissue are consistent with those identified by CNV pathway enrichment analyses in living autistic patients [26].

Conclusion

In this study, we found evidence for distinct gene expression anomalies in the prefrontal cortex of young autistic individuals that may underlie structural and functional maldevelopment of this and other association cortices. Our evidence shows that some important gene expression abnormalities in the prefrontal cortex change with age in autism and such changes may be related to findings in other studies that report a shift in morphology and function in the adult autistic brain. Enrichment of CNVs and association analysis of cell cycle gene sets, in accordance with early expression defects of cell cycle mechanisms, suggest that genetic variation may contribute to this dysregulation. We also found that irrespective of age, the expression of atypical developmental processes distinguish the autistic brain from that of control individuals. The modulation of these expression mechanisms may underlie the abnormal brain growth trajectory in autism. Further knowledge of the specific developmental neurobiological mechanisms behind the age-dependent anomalies reported here could point to distinct early developmental processes that lead to autism, uncover mechanisms that respond to early pathologies in the mature brain and suggest novel molecular targets for prevention strategies and treatment over the course of the disorder.

Materials and Methods

Gene expression analysis

Ethics statement

All cases are deceased and are deidentified by the brain banks where tissue was obtained. However, the same human protections procedures were employed as for live subjects. Research procedures employed in this study were approved by the institutional review board of the University of California, San Diego (protocol number 091205).

RNA extraction and quantification

A full description of the methods is provided in Text S1. Extraction of total RNA from 5–10 mg of frozen brain tissue from grey and white matter of prefrontal cortex of 57 postmortem autism and control cases aged 2–56 years was performed using the Ambion MELT kit according to manufacturer's instructions. Select samples were analyzed using Bioanalyzer (Agilent) according to the manufacturer's protocol for quality control and quantification (Table S1). RNA from remaining samples was quantified using a NanoDrop spectrophotometer.

Microarray processing

Four hundred fifty ng of total RNA from each of 57 cases was submitted to Illumina, Inc. (San Diego, CA) for DASL-based labeling and hybridization to the Illumina HumanRef8 v3 microarray. Using biotinylated random primers and oligo-dT, 200 ng RNA was converted to cDNA. The biotinylated cDNA was then immobilized to a streptavidin-coated solid support and annealed by 24526 pairs of oligonucleotides (18626 genes). Following extension and ligation, the ligated oligonucleotides were PCR-amplified with biotinylated or fluorophore-labeled universal primers and captured using streptavidin paramagnetic beads. Finally, the products were washed and denatured before hybridization to the BeadChips at 58°C for 16 hours. A BeadArray Reader extracted images and read fluorescence intensities, and all data was uploaded into BeadStudio software for quality control and processing.

Data preprocessing

Raw data exported from Illumina's BeadStudio underwent outlier removal, log2 transformation and quantile normalization as implemented in the lumi package for R/Bioconductor [75]. To simultaneously remove variance attributed to batch and seizures, we performed batch and covariate correction using ComBat [76]. Multivariate Distance Matrix Regression [77] with 10,000 permutations confirmed that variance attributable to batch and seizures were decreased following correction. Detailed information regarding the methodology for normalizing gene expression data and removing outliers is provided in Chow et al. [78].

Statistical analysis

Filtering and differential expression analyses were performed using BRBArrayTools (http://linus.nci.nih.gov/BRBArrayTools.html). Filtering was performed based on variance and minimum intensity. Probes with <20% of expression values having at least a 1.5-fold up- or down-regulation from the gene's median value across cases, and probes with a minimum log intensity of less than 15 were excluded.

We identified 1086 probes with an interaction effect of age and diagnosis by performing a two-way analysis of variance with 2 levels of diagnosis (autism and control) and 2 levels of categorical age (2–14 years and 15–56 years, n

33). Interaction probes of p<0.05, corresponding to an empirical FDR of 0.27 [79], were selected for posthoc analysis to examine which differences were driven by the young autism and young control groups and the adult autism and adult control groups by t-tests (p<0.05) to investigate gene expression changes in the young and adult autistic brain. Probes exhibiting a main effect of diagnosis across age groups were also identified (p<0.05, FDR

0.13).

Enrichment analysis

Enrichment analyses were performed using the MetaCore software suite (www.genego.com/metacore.php) and DAVID (http://david.abcc.ncifcrf.gov/) to examine the biological and functional relevance of differentially expressed genes. These genes were uploaded into MetaCore and filtered for known expression specific to the brain or the fetal brain. The default background gene list was used for all enrichment analyses. All results met threshold of corrected p<0.05 and FDR<0.1 [80]. Gene references used to confirm categorizations by MetaCore are listed in Table SXPATH ERROR: unknown variable "checknextn".XPATH ERROR: unknown variable "checknextn".

Independent validation of microarray results

RNA from 1 male autistic and 1 control case both 31 years old were analyzed using SYBR green RT-PCR to validate the intensity values detected by microarray of 19 genes (Figure S2). Primer3 software [81] was used to design primers across splice junctions to produce amplicons of ~200 bp.

One mg of total RNA was used for cDNA synthesis using random hexamers and AMV reverse transcriptase. An equivalent of 50 ng of RNA was processed by qPCR using Roche's LightCycler rapid thermal cycler system (Roche Diagnostics Ltd, Lewes, UK) according to the manufacturer's instructions in a 96-well, 10 µL format using standard PCR conditions. One µL of cDNA template, 250 nM of forward and reverse primer and 5 µL of PCR Master Mix (Roche) were mixed for each reaction.

We took the geometric mean of all reference genes and the difference between this mean and the average intensity of experimental genes to find the delta Ct for each experimental gene. Subsequently, log2 fold change was assessed using -(T-C) where T

delta Ct of gene of the autistic case and C

delta Ct of gene of the control case. Using Spearman's rank correlation, the log2 fold changes of these 19 genes across qPCR and microarray platforms were found to be correlated at R

0.78 (p

0.000075, DF

17; Figure S2).

Comparison between studies

Unique ProbeIDs of differentially expressed in the ‘initial’ dataset from Voineagu et al. [20] (file

‘nature10110-s3.xls’) were compared with the differential expression gene list in the present study comparing all autism and control cases. Genes overlapping in each study with the present one were subjected to enrichment analysis in MetaCore.

Copy Number Variation (CNV) detection and association analysis

Fifty-five samples were genotyped on the Illumina 660 Bead Array (Illumina Inc., San Diego, California) and SNP calls were made using the Illumina Genome Studio software.

CNV calls were first obtained using the PennCNV software (http://www.openbioinformatics.org/penncnv/) implementing the wave adjustment procedure via the “–gcmodel” argument [53] and then using the CNVision pipeline [54] to select for high confidence CNV calls.

We first analyzed only male cases that passed QC (12 autism and 12 controls; Figure 4) and identified a total of about 850 CNVs. Known nonpathogenic regions reported in the Database of Genomic Variants (http://projects.tcag.ca/cgi-bin/variation/gbrowse/hg18) were filtered without upper size limits. No large-size CNVs (>1 Mb) were identified in single cases that could potentially drive the gene enrichment results. We next analyzed males and female cases together (14 autism and 16 controls; Figure S4) using the same parameters and identified a total of about 1300 CNVs and then proceeded with the filtering of common regions. We also excluded the possibility of a biased CNV detection given the small sample size (Text S1 and Figure S4).

Due to possible high false positive rates, we re-analyzed all cases using CNVision, a recently described analysis pipeline [54] (www.cnvision.org) that merges results of PennCNV, QuantiSNP and GNOSIS. The analysis of the male cases yielded about 350 CNVs (11 autism and 13 controls). Gene enrichment was performed considering both the gene content of gene-rich CNVs and the nearest gene at the 5- and 3-prime end of gene-desert CNVs. As performed with PennCNV alone, we next analyzed male and female cases together but were unable to compare the gene enrichment of the two categories due to the significant difference in the number of cases that passed QC (12 autism versus 19 controls).

GO enrichment of the gene content of these regions was also performed using the MetaCore software suite (FDR<0.01 and p<0.05). GeneGO Network Processes of each of these gene lists are reported in Figure 4 and Figure S4.

Gene association analysis

For gene association analysis we utilized the AGRE-NIMH Broad/Johns Hopkins Medical Institute (Broad/JHMI) sample as our experimental dataset using original quality control filters and the Children's Hospital of Philadelphia (CHOP) sample dataset as a replication sample, as previously described [56].

Gene sets were created using Gene Ontology (GO; http://www.geneontology.org/), GeneGO (http://www.genego.com/metacore.php) and the Wnt homepage (http://www.stanford.edu/group/nusselab/cgi-bin/wnt/). We used PLINK [82] (http://pngu.mgh.harvard.edu/~purcell/plink/) to retrieve the SNPs within a window of 20 kb around each gene and to perform set-based association analysis.

Significantly associated pathways (p<0.05) in the cell cycle gene set were then broken down into 21 subsets of genes denoting specific phases of the cell cycle using Ingenuity and set-based tests were again performed on the experimental dataset. Subsets that were found to be significant in the Broad/JHMI sample were then tested on the CHOP sample for replication using the same set-based analysis.

Supporting Information

Figure S1

Venn diagram showing differentially expressed genes in young autism vs. young control, adult autism vs. adult control and diagnosis main effect ANOVA analyses.

(TIF)

Click here for additional data file.^{(1.4M, tif)}

Figure S2

Log2 fold change correlations of selected genes detected by microarray and RT-PCR, and primer sequences. (A) Log2 Fold change detected by RT-PCR is depicted on the x-axis, and change detected by microarray is on the y-axis. Spearman's rank correlation detected R

0.78 (p

0.000075, DF

17) correlation between microarray and qPCR detection of fold change. (B) Forward and reverse primer sequences for 19 experimental and 3 reference genes used for RT-PCR to validate gene expression microarray results.

(TIF)

Click here for additional data file.^{(3.3M, tif)}

Figure S3

Third most significant map folder of diagnosis main effect analysis. Graph on left shows fold change of genes in Immune Response Map Folder. This map folder was third most significant in the comparison between all autistic and all control cases. From each category of differentially expressed genes in the all autistic vs. all control comparison (Table S5), networks were created using MetaCore Network Analysis. Genes with blue circles were differentially expressed; genes without circles were summoned by the database to complete network.

(TIF)

Click here for additional data file.^{(6.6M, tif)}

Figure S4

Enrichment of CNVs detected in the DLPFC of male and female samples. Metacore analysis of GeneGO Processes significantly represented in genes contained within: (A) total CNVs and B) filtered (i.e., not present in the Database of Genomic Variants) CNVs. Blue bars, controls. Red bars, autistic cases. C) Average number of CNVs in autistic cases and controls. D) Average number of genes per CNV in autistic and control cases. E) Average CNV size comparison between autistic cases and controls. C–E) No statistically significant differences were found between autistic cases and controls, suggesting non-biased CNV detection potentially due to the small sample size. F) Size distribution of the filtered CNVs in the autistic cases is shown.

(TIF)

Click here for additional data file.^{(1.3M, tif)}

Table S1

Demographics and clinical information of postmortem cases. (A) ID, diagnosis, age, gender, study, DLPFC RNA integrity number (RIN), basis of diagnosis, ADI measures, and intellectual disability for cases in present study are documented. RIN #1 was performed at the UCSD Biogem core, RIN #2 was performed at UCSF in the Wynshaw-Boris lab, and RIN #3 was performed at the Allen Institute. ADI-R

Autism Diagnostic Interview-Revised; ADOS

Autism Diagnostic Observation Schedule; CNV

copy number variation; ISH

in situ hybridization; Comm

Communication; R & R

Restricted and Repetitive behavior; DLPFC

Dorsolateral Prefrontal Cortex; RIN

RNA integrity number; M

male; F

female; v

verbal; nv

nonverbal; Y

yes; N

no; TARF

existing diagnostic status on donation from The Autism Research Foundation, no other records available; ATP

existing diagnostic status on case from the Autism Tissue Program, no documents available at this date. Pink X

case passed quality control measures for gene expression/CNV analysis; black X

case was processed but did not pass quality control measures for CNV analysis. (B). Detailed clinical information of autistic cases. Available clinical information, including information from the ADI-R assessment, noted seizure activity and intellectual disability, is provided for autistic cases in this study. Assessments were made by a clinical psychologist (C.C.B.). ADI

Autism Diagnostic Interview; RIN

RNA Integrity Score; HX

History; DO

Diagnosis; ADI Comm Score

ADI-R Communication Score; ADI R&R Score

ADI-R Restricted and Repetitive Behavior Score; IVF

In Vitro Fertilization. (C) Detailed clinical information of autistic and control cases. Available clinical information is provided for autistic and control cases in this study. Assessments were made by a clinical psychologist (C.C.B.). HX

History; DO

Diagnosis; IVF

In Vitro Fertilization; PMI

Postmortem Interval.

(PDF)

Click here for additional data file.^{(226K, pdf)}

Table S2

Differentially expressed genes in young autistic cases. All 102 differentially expressed genes in the posthoc comparison passing a threshold of p<0.05 between young autism and young control cases of genes showing an effect of interaction between diagnosis and categorical age. Gene symbols, Illumina probe IDs, p-Value of difference, cytogenetic bands and fold changes are listed. Bold genes are shown in Figure 1.

(PDF)

Click here for additional data file.^{(111K, pdf)}

Table S3

Dysregulated genes of young autistic cases and previously identified candidate genes and loci. Loci of 102 differentially expressed genes in the posthoc comparison and references of previous linkage/association/CNV studies implicating the candidate locus and references of other genes neighboring the candidate loci are listed. NEGATIVE

negative association/linkage.

(PDF)

Click here for additional data file.^{(98K, pdf)}

Table S4

Top downregulated and upregulated genes in adult autistic cases. Genes showing greatest fold change difference in the posthoc comparison passing a threshold of p<0.05 between adult autism and adult control cases of genes showing an effect of interaction between diagnosis and categorical age. Gene symbols, Illumina probe IDs, p-Value of difference, cytogenetic bands and fold changes are listed.

(PDF)

Click here for additional data file.^{(150K, pdf)}

Table S5

Top downregulated and upregulated genes of male autistic cases across all young and older ages (2 to 56 years). Genes showing greatest fold change differences and a main effect of diagnosis passing a threshold of p<0.05 between autism and control cases, Illumina probe IDs, p-value of difference, cytogenetic bands and fold changes are listed.

(PDF)

Click here for additional data file.^{(149K, pdf)}

Table S6

Significant dysregulated pathways of autistic cases across all young and older ages (2 to 56 years). Dysregulated pathways enriched in genes showing a main effect of diagnosis (p<0.05; FDR<0.1) identified using the MetaCore software suite between autism and control cases, p-value and network objects are listed. Pathways are sorted by pathway category name.

(PDF)

Click here for additional data file.^{(87K, pdf)}

Table S7

Chromosomal locations of CNV regions found in all autistic cases (males and females). Chromosomal location, number (N) of SNPs, size of the SNP in base pairs (bp) and annotated gene content of CNV regions found in all autistic cases (males and females) are listed. Overlapping regions with the same gene content but different breakpoints are listed as distinct CNVs. Enrichment results are presented in Figure 4.

(PDF)

Click here for additional data file.^{(158K, pdf)}

Table S8

Chromosomal locations of CNV regions found in all control cases (males and females). Chromosomal location, number (N) of SNPs, size of the SNP in base pairs (bp) and annotated gene content of CNV regions found in all control cases (males and females) are listed. Overlapping regions with the same gene content but different breakpoints are listed as distinct CNVs. Enrichment results are presented in Figure 4.

(PDF)

Click here for additional data file.^{(190K, pdf)}

Table S9

References for genes in noted pathways and networks. Important genes from the pathways and networks identified by gene expression analyses are listed. Gene category, references, and analysis corresponding to these genes are presented. Gex

gene expression.

(PDF)

Click here for additional data file.^{(80K, pdf)}

Text S1

Supporting materials. Supplementary methods, acknowledgements and figures are provided.

(DOCX)

Click here for additional data file.^{(104K, docx)}

Acknowledgments

We thank all parents for the donation of brain tissue from their loved ones. Tissue for this study was provided by the NICHD Brain and Tissue Bank for Developmental Disorders, the Brain and Tissue Bank for Developmental Disorders, Autism Tissue Program, and Harvard Brain Tissue Resource Center. Additional acknowledgements are listed in Text S1.

Footnotes

J-BF and CA declare stock and employment interest in Illumina, Inc.

This research was supported by Cure Autism Now, the Simons Foundation, The Peter Emch Family Foundation, Autism Speaks, The Thursday Club Juniors, the Rady Children's Hospital of San Diego, and the UCSD-NIH Autism Center of Excellence (P50-MH081755). NJS and MEW are funded in part by part by the following National Institutes of Health research grants: U19 AG023122-01, R01 MH078151-01A1, N01 MH22005, U01 DA024417-01, UL1 RR025774, RC2 DA029475, R01 AG031224, U54 NS056883, as well as grants from the Price Foundation and Scripps Genomic Medicine. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

1. Ozonoff S, Heung K, Byrd R, Hansen R, Hertz-Picciotto I. The onset of autism: patterns of symptom emergence in the first years of life. Autism research: official journal of the International Society for Autism Research. 2008;1:320–328. [PMC free article] [PubMed]

2. Courchesne E, Karns CM, Davis HR, Ziccardi R, Carper RA, et al. Unusual brain growth patterns in early life in patients with autistic disorder: an MRI study. Neurology. 2001;57:245–254. [PubMed]

3. Carper RA, Moses P, Tigue ZD, Courchesne E. Cerebral lobes in autism: early hyperplasia and abnormal age effects. NeuroImage. 2002;16:1038–1051. [PubMed]

4. Sparks BF, Friedman SD, Shaw DW, Aylward EH, Echelard D, et al. Brain structural abnormalities in young children with autism spectrum disorder. Neurology. 2002;59:184–192. [PubMed]

5. Schumann CM, Hamstra J, Goodlin-Jones BL, Lotspeich LJ, Kwon H, et al. The amygdala is enlarged in children but not adolescents with autism; the hippocampus is enlarged at all ages. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2004;24:6392–6401. [PubMed]

6. Carper RA, Courchesne E. Localized enlargement of the frontal cortex in early autism. Biological psychiatry. 2005;57:126–133. [PubMed]

7. Hazlett HC, Poe M, Gerig G, Smith RG, Provenzale J, et al. Magnetic resonance imaging and head circumference study of brain size in autism: birth through age 2 years. Archives of general psychiatry. 2005;62:1366–1376. [PubMed]

8. Redcay E, Courchesne E. When is the brain enlarged in autism? A meta-analysis of all brain size reports. Biological psychiatry. 2005;58:1–9. [PubMed]

9. Munson J, Dawson G, Abbott R, Faja S, Webb SJ, et al. Amygdalar volume and behavioral development in autism. Archives of general psychiatry. 2006;63:686–693. [PubMed]

10. Schumann CM, Barnes CC, Lord C, Courchesne E. Amygdala enlargement in toddlers with autism related to severity of social and communication impairments. Biological psychiatry. 2009;66:942–949. [PMC free article] [PubMed]

11. Schumann CM, Bloss CS, Barnes CC, Wideman GM, Carper RA, et al. Longitudinal magnetic resonance imaging study of cortical development through early childhood in autism. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2010;30:4419–4427. [PMC free article] [PubMed]

12. Hazlett HC, Poe MD, Gerig G, Styner M, Chappell C, et al. Early brain overgrowth in autism associated with an increase in cortical surface area before age 2 years. Arch Gen Psychiatry. 2011;68:467–476. [PMC free article] [PubMed]

13. Courchesne E, Campbell K, Solso S. Brain growth across the life span in autism: age-specific changes in anatomical pathology. Brain Res. 2011;1380:138–145. [PubMed]

14. Redcay E, Courchesne E. Deviant functional magnetic resonance imaging patterns of brain activity to speech in 2–3-year-old children with autism spectrum disorder. Biological psychiatry. 2008;64:589–598. [PMC free article] [PubMed]

15. Eyler L, Pierce K*, Courchesne E*. A Failure of Left Temporal Cortex to Specialize for Language is an Early Emerging and Fundamental Property of Autism. Brain in press [PMC free article] [PubMed]

16. Pierce K, Eyler L. Structural and Functional Brain Development in ASD: The Impact of Early Brain Overgrowth and Considerations for Treatment. In: Fein D, editor. The Neuropsychology of Autism. New York, NY: Oxford University Press; 2011. pp. 407–450.

17. Courchesne E, Mouton PR, Calhoun ME, Semendeferi K, Ahrens-Barbeau C, et al. Neuron number and size in prefrontal cortex of children with autism. JAMA. 2011;306:2001–2010. [PubMed]

18. Stanfield AC, McIntosh AM, Spencer MD, Philip R, Gaur S, et al. Towards a neuroanatomy of autism: a systematic review and meta-analysis of structural magnetic resonance imaging studies. Eur Psychiatry. 2008;23:289–299. [PubMed]

19. Courchesne E, Pierce K, Schumann CM, Redcay E, Buckwalter JA, et al. Mapping early brain development in autism. Neuron. 2007;56:399–413. [PubMed]

20. Voineagu I, Wang X, Johnston P, Lowe JK, Tian Y, et al. Transcriptomic analysis of autistic brain reveals convergent molecular pathology. Nature. 2011;474:380–384. [PMC free article] [PubMed]

21. Araghi-Niknam M, Fatemi SH. Levels of Bcl-2 and P53 are altered in superior frontal and cerebellar cortices of autistic subjects. Cellular and molecular neurobiology. 2003;23:945–952. [PubMed]

22. Garbett K, Ebert PJ, Mitchell A, Lintas C, Manzi B, et al. Immune transcriptome alterations in the temporal cortex of subjects with autism. Neurobiology of disease. 2008;30:303–311. [PMC free article] [PubMed]

23. Vargas DL, Nascimbene C, Krishnan C, Zimmerman AW, Pardo CA. Neuroglial activation and neuroinflammation in the brain of patients with autism. Annals of neurology. 2005;57:67–81. [PubMed]

24. Oblak AL, Gibbs TT, Blatt GJ. Decreased GABA(B) Receptors in the Cingulate Cortex and Fusiform Gyrus in Autism. Journal of neurochemistry. 2010;114:1414–1423. [PMC free article] [PubMed]

25. Sebat J, Lakshmi B, Malhotra D, Troge J, Lese-Martin C, et al. Strong association of de novo copy number mutations with autism. Science (New York, NY) 2007;316:445–449. [PMC free article] [PubMed]

26. Pinto D, Pagnamenta AT, Klei L, Anney R, Merico D, et al. Functional impact of global rare copy number variation in autism spectrum disorders. Nature. 2010;466:368–372. [PMC free article] [PubMed]

27. April C, Klotzle B, Royce T, Wickham-Garcia E, Boyaniwsky T, et al. Whole-genome gene expression profiling of formalin-fixed, paraffin-embedded tissue samples. PLoS ONE. 2009;4:e8162. doi: 10.1371/journal.pone.0008162. [PMC free article] [PubMed]

28. Fan J-B, Yeakley JM, Bibikova M, Chudin E, Wickham E, et al. A versatile assay for high-throughput gene expression profiling on universal array matrices. Genome research. 2004;14:878–885. [PubMed]

29. Abramovitz M, Ordanic-Kodani M, Wang Y, Li Z, Catzavelos C, et al. Optimization of RNA extraction from FFPE tissues for expression profiling in the DASL assay. BioTechniques. 2008;44:417–423. [PMC free article] [PubMed]

30. Huang DW, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic acids research. 2009;37:1–13. [PMC free article] [PubMed]

31. Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nature protocols. 2009;4:44–57. [PubMed]

32. Freese JL, Pino D, Pleasure SJ. Wnt signaling in development and disease. Neurobiology of disease. 2010;38:148–153. [PMC free article] [PubMed]

33. Lijam N, Paylor R, McDonald M, Crawley J, Deng C, et al. Social Interaction and Sensorimotor Gating Abnormalities in Mice Lacking Dvl1. Cell. 1997;90:895–905. [PubMed]

34. Wigle JT, Eisenstat DD. Homeobox genes in vertebrate forebrain development and disease. Clinical genetics. 2008;73:212–226. [PubMed]

35. Schier AF. Nodal morphogens. Cold Spring Harbor perspectives in biology. 2009;1:a003459. [PMC free article] [PubMed]

36. Chen Z, Palmer TD. Cellular repair of CNS disorders: an immunological perspective. Human molecular genetics. 2008;17:R84–92. [PubMed]

37. Lie DC, Song H, Colamarino SA, Ming G-l, Gage FH. 2004. NEUROGENESIS IN THE ADULT BRAIN: New Strategies for Central Nervous System Diseases.

38. Lai M, Gluckman P, Dragunow M, Hughes PE. Focal brain injury increases activin betaA mRNA expression in hippocampal neurons. Neuroreport. 1997;8:2691–2694. [PubMed]

39. Ageta H, Murayama A, Migishima R, Kida S, Tsuchida K, et al. Activin in the brain modulates anxiety-related behavior and adult neurogenesis. PLoS ONE. 2008;3:e1869. doi: 10.1371/journal.pone.0001869. [PMC free article] [PubMed]

40. Latres E, Chiaur DS, Pagano M. The human F box protein beta-Trcp associates with the Cul1/Skp1 complex and regulates the stability of beta-catenin. Oncogene. 1999;18:849–854. [PubMed]

41. Madsen T. Chronic electroconvulsive seizure up-regulates β-catenin expression in rat hippocampus: role in adult neurogenesis. Biological Psychiatry. 2003;54:1006–1014. [PubMed]

42. Kuwabara T, Hsieh J, Muotri A, Yeo G, Warashina M, et al. Wnt-mediated activation of NeuroD1 and retro-elements during adult neurogenesis. Nature neuroscience. 2009;12:1097–1105. [PMC free article] [PubMed]

43. Lim DA, Tramontin AD, Trevejo JM, Herrera DG, García-Verdugo JM, et al. Noggin antagonizes BMP signaling to create a niche for adult neurogenesis. Neuron. 2000;28:713–726. [PubMed]

44. Groszer M, Erickson R, Scripture-Adams DD, Lesche R, Trumpp A, et al. Negative regulation of neural stem/progenitor cell proliferation by the Pten tumor suppressor gene in vivo. Science (New York, NY) 2001;294:2186–2189. [PubMed]

45. Butler MG, Dasouki MJ, Zhou X-P, Talebizadeh Z, Brown M, et al. Subset of individuals with autism spectrum disorders and extreme macrocephaly associated with germline PTEN tumour suppressor gene mutations. Journal of medical genetics. 2005;42:318–321. [PMC free article] [PubMed]

46. Page DT, Kuti OJ, Prestia C, Sur M. Haploinsufficiency for Pten and Serotonin transporter cooperatively influences brain size and social behavior. Proceedings of the National Academy of Sciences of the United States of America. 2009;106:1989–1994. [PubMed]

47. Hay N. The Akt-mTOR tango and its relevance to cancer. Cancer cell. 2005;8:179–183. [PubMed]

48. Orlova KA, Crino PB. The tuberous sclerosis complex. Annals of the New York Academy of Sciences. 2010;1184:87–105. [PMC free article] [PubMed]

49. Chenn A, Walsh CA. Regulation of cerebral cortical size by control of cell cycle exit in neural precursors. Science (New York, NY) 2002;297:365–369. [PubMed]

50. Tissir F, Goffinet AM. Reelin and brain development. Nature reviews Neuroscience. 2003;4:496–505. [PubMed]

51. Persico AM, D'Agruma L, Maiorano N, Totaro A, Militerni R, et al. Reelin gene alleles and haplotypes as a factor predisposing to autistic disorder. Molecular psychiatry. 2001;6:150–159. [PubMed]

52. Wynshaw-Boris A, Pramparo T, Youn YH, Hirotsune S. Lissencephaly: mechanistic insights from animal models and potential therapeutic strategies. Seminars in cell & developmental biology. 2010;21:823–830. [PMC free article] [PubMed]

53. Wang K, Li M, Hadley D, Liu R, Glessner J, et al. PennCNV: an integrated hidden Markov model designed for high-resolution copy number variation detection in whole-genome SNP genotyping data. Genome research. 2007;17:1665–1674. [PubMed]

54. Sanders SJ, Ercan-Sencicek AG, Hus V, Luo R, Murtha MT, et al. Multiple Recurrent De Novo CNVs, Including Duplications of the 7q11.23 Williams Syndrome Region, Are Strongly Associated with Autism. Neuron. 2011;70:863–885. [PubMed]

55. Wang K, Zhang H, Ma D, Bucan M, Glessner JT, et al. Common genetic variants on 5p14.1 associate with autism spectrum disorders. Nature. 2009;459:528–533. [PMC free article] [PubMed]

56. Weiss LA, Arking DE, Daly MJ, Chakravarti A. A genome-wide linkage and association scan reveals novel loci for autism. Nature. 2009;461:802–808. [PMC free article] [PubMed]

57. Carreira BP, Morte MI, Inacio A, Costa G, Rosmaninho-Salgado J, et al. Nitric oxide stimulates the proliferation of neural stem cells bypassing the epidermal growth factor receptor. Stem Cells. 2010;28:1219–1230. [PubMed]

58. Wei CJ, Li W, Chen JF. Normal and abnormal functions of adenosine receptors in the central nervous system revealed by genetic knockout studies. Biochim Biophys Acta. 2011;1808:1358–1379. [PubMed]

59. Pierce K, Eyler L. Structural and Functional Brain Development In Autism: The Impact of Early Brain Overgrowth and Considerations for Treatment. In: Fein Deborah., editor. Oxford University Press, The Neuropsychology of Autism; 2011. pp. 407–450.

60. Courchesne E, Pierce K. Why the frontal cortex in autism might be talking only to itself: local over-connectivity but long-distance disconnection. Current opinion in neurobiology. 2005;15:225–230. [PubMed]

61. Courchesne E, Pierce K. Brain overgrowth in autism during a critical time in development: implications for frontal pyramidal neuron and interneuron development and connectivity. Int J Dev Neurosci. 2005;23:153–170. [PubMed]

62. Courchesne E, Campbell K, Solso S. Brain Growth Across the Life Span in Autism: Age-Specific Changes in Anatomical Pathology. Brain research 2010 [PubMed]

63. Bonaguidi MA, Peng CY, McGuire T, Falciglia G, Gobeske KT, et al. Noggin expands neural stem cells in the adult hippocampus. J Neurosci. 2008;28:9194–9204. [PubMed]

64. Gajera CR, Emich H, Lioubinski O, Christ A, Beckervordersandforth-Bonk R, et al. LRP2 in ependymal cells regulates BMP signaling in the adult neurogenic niche. J Cell Sci. 2010;123:1922–1930. [PubMed]

65. Frank CL, Ge X, Xie Z, Zhou Y, Tsai LH. Control of activating transcription factor 4 (ATF4) persistence by multisite phosphorylation impacts cell cycle progression and neurogenesis. J Biol Chem. 2010;285:33324–33337. [PMC free article] [PubMed]

66. Zhang C, Wu H, Zhu X, Wang Y, Guo J. Role of transcription factors in neurogenesis after cerebral ischemia. Rev Neurosci. 2011;22:457–465. [PubMed]

67. Ohira K. Injury-induced neurogenesis in the mammalian forebrain. Cell Mol Life Sci. 2011;68:1645–1656. [PubMed]

68. Ideker T, Dutkowski J, Hood L. Boosting signal-to-noise in complex biology: prior knowledge is power. Cell. 2011;144:860–863. [PMC free article] [PubMed]

69. Boulanger LM, Shatz CJ. Immune signalling in neural development, synaptic plasticity and disease. Nat Rev Neurosci. 2004;5:521–531. [PubMed]

70. O'Driscoll M, Jeggo PA. The role of the DNA damage response pathways in brain development and microcephaly: insight from human disorders. DNA Repair (Amst) 2008;7:1039–1050. [PubMed]

71. Kim WR, Sun W. Programmed cell death during postnatal development of the rodent nervous system. Dev Growth Differ. 2011;53:225–235. [PubMed]

72. Onore C, Careaga M, Ashwood P. The role of immune dysfunction in the pathophysiology of autism. Brain Behav Immun 2011

73. Widera D, Mikenberg I, Elvers M, Kaltschmidt C, Kaltschmidt B. Tumor necrosis factor alpha triggers proliferation of adult neural stem cells via IKK/NF-kappaB signaling. BMC Neurosci. 2006;7:64. [PMC free article] [PubMed]

74. Stellwagen D, Malenka RC. Synaptic scaling mediated by glial TNF-alpha. Nature. 2006;440:1054–1059. [PubMed]

75. Du P, Kibbe WA, Lin SM. lumi: a pipeline for processing Illumina microarray. Bioinformatics (Oxford, England) 2008;24:1547–1548. [PubMed]

76. Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics (Oxford, England) 2007;8:118–127. [PubMed]

77. Zapala MA, Schork NJ. Multivariate regression analysis of distance matrices for testing associations between gene expression patterns and related variables. Proceedings of the National Academy of Sciences of the United States of America. 2006;103:19430–19435. [PubMed]

78. Chow M, Winn M, Li H, April C, Barnes CC, et al. in press. Genome-wide Brain Gene Expression Microarray Data Preprocessing and Quality Control Scheme using the Illumina DASL Assay.

79. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: a Practical and Powerful Approach to Multiple Testing. J R Statist Soc. 1995;57:289–300.

80. Falcon S, Gentleman R. Using GOstats to test gene lists for GO term association. Bioinformatics (Oxford, England) 2007;23:257–258. [PubMed]

81. Rozen S, Skaletsky H. Primer3 on the WWW for General Users and for Biologist Programmers. Methods. 2003;132 [PubMed]

82. Purcell S, Neale B, Toddbrown K, Thomas L, Ferreira M, et al. PLINK: A Tool Set for Whole-Genome Association and Population-Based Linkage Analyses. The American Journal of Human Genetics. 2007;81:559–575. [PubMed]

Articles from PLoS Genetics are provided here courtesy of
Public Library of Science